Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3953632
Max Phase: Preclinical
Molecular Formula: C45H51ClN8O9S2
Molecular Weight: 947.54
Molecule Type: Small molecule
Associated Items:
ID: ALA3953632
Max Phase: Preclinical
Molecular Formula: C45H51ClN8O9S2
Molecular Weight: 947.54
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CN(S(C)(=O)=O)CCO5)c([N+](=O)[O-])c4)c(Oc4cccc5[nH]cnc45)c3)CC2)=C(c2ccc(Cl)cc2)C1
Standard InChI: InChI=1S/C45H51ClN8O9S2/c1-45(2)16-15-31(37(25-45)30-7-9-32(46)10-8-30)27-51-17-19-52(20-18-51)33-11-13-36(42(23-33)63-41-6-4-5-39-43(41)49-29-48-39)44(55)50-65(60,61)35-12-14-38(40(24-35)54(56)57)47-26-34-28-53(21-22-62-34)64(3,58)59/h4-14,23-24,29,34,47H,15-22,25-28H2,1-3H3,(H,48,49)(H,50,55)
Standard InChI Key: JZAWPVMEFGREHJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 947.54 | Molecular Weight (Monoisotopic): 946.2909 | AlogP: 6.89 | #Rotatable Bonds: 14 |
Polar Surface Area: 209.41 | Molecular Species: ACID | HBA: 13 | HBD: 3 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.18 | CX Basic pKa: 7.95 | CX LogP: 4.93 | CX LogD: 5.08 |
Aromatic Rings: 5 | Heavy Atoms: 65 | QED Weighted: 0.08 | Np Likeness Score: -1.20 |
1. (2015) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, |
Source(1):